These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19060243)

  • 1. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.
    Whitecross KF; Alsop AE; Cluse LA; Wiegmans A; Banks KM; Coomans C; Peart MJ; Newbold A; Lindemann RK; Johnstone RW
    Blood; 2009 Feb; 113(9):1982-91. PubMed ID: 19060243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.
    Mason KD; Vandenberg CJ; Scott CL; Wei AH; Cory S; Huang DC; Roberts AW
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17961-6. PubMed ID: 19004807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
    He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
    Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
    Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
    Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
    Wiegmans AP; Alsop AE; Bots M; Cluse LA; Williams SP; Banks KM; Ralli R; Scott CL; Frenzel A; Villunger A; Johnstone RW
    Cancer Res; 2011 May; 71(10):3603-15. PubMed ID: 21398407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
    Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
    Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
    Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
    Tsao T; Shi Y; Kornblau S; Lu H; Konoplev S; Antony A; Ruvolo V; Qiu YH; Zhang N; Coombes KR; Andreeff M; Kojima K; Konopleva M
    Ann Hematol; 2012 Dec; 91(12):1861-70. PubMed ID: 22893484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.
    Kutuk O; Letai A
    Cancer Res; 2008 Oct; 68(19):7985-94. PubMed ID: 18829556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
    Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model.
    Mills JR; Malina A; Lee T; Di Paola D; Larsson O; Miething C; Grosse F; Tang H; Zannis-Hadjopoulos M; Lowe SW; Pelletier J
    Blood; 2013 Apr; 121(17):3402-12. PubMed ID: 23440244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
    Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
    Newbold A; Lindemann RK; Cluse LA; Whitecross KF; Dear AE; Johnstone RW
    Mol Cancer Ther; 2008 May; 7(5):1066-79. PubMed ID: 18483296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
    Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.